NASDAQ · Drug Manufacturers - Specialty & Generic

EOLS (EOLS) Stock

$6.03 -3.05% NASDAQ: EOLS Healthcare

Valuation

MetricValue
Price$6.03
Market Cap$397.10M
P/E Ratio-9.25
P/B Ratio-14.00
P/S Ratio1.35
EPS (TTM)$-0.80
52-Week High$9.58
52-Week Low$3.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE174.92%
ROA-19.68%
ROCE-18.91%
Gross Margin-12.79%
Operating Margin-12.79%
Net Margin-14.39%
Debt/Equity-5.73
Current Ratio1.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$100.0M$149.0M$202.0M$266.0M$297.0M
Operating Profit$-44.0M$-65.0M$-49.0M$-34.0M$-38.0M
Net Profit$-47.0M$-74.0M$-62.0M$-50.0M$-52.0M
EPS$-0.94$-1.33$-1.08$-0.81$-0.80
Op Margin-44.5%-44.0%-24.4%-12.9%-12.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$257.0M$178.0M$189.0M$233.0M$226.0M
Total Liabilities$176.0M$159.0M$210.0M$227.0M$249.0M
Cash$146.0M$54.0M$63.0M$87.0M$54.0M
Borrowings$75.0M$74.0M$127.0M$130.0M$155.0M

Latest News

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire · Jul 10, 2026 Evolus Partners With IBSA to Develop, Commercialize Profhilo in US MT Newswires · Jul 8, 2026 Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality Business Wire · Jul 8, 2026 3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80% Simply Wall St. · May 15, 2026 Evolus Plans to Launch Estyme Collection in Europe MT Newswires · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-33.0M$-85.0M$-34.0M$-18.0M$-42.0M
Investing Cash Flow$3.0M$-6.0M$-3.0M$-6.0M$-17.0M
Financing Cash Flow$-6.0M$-4.0M$-5.0M$-4.0M$16.0M
Net Cash Flow$44.0M$-92.0M$9.0M$24.0M$-33.0M
Free Cash Flow$-34.0M$-88.0M$-36.0M$-19.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.37
EV / EBITDA-37.21
FCF Yield-12.84%
Quick Ratio1.55
Interest Coverage-1.90
Return 1Y-37.47%
Return 3Y-16.92%
Return 5Y-46.31%

Ownership

Insiders Held14.68%
Institutions Held70.35%
Institutions Float Held82.46%
Institutional HolderSharesReport Date
Nantahala Capital Management, LLC6,376,8572026-03-31
Blackrock Inc.4,290,3832026-03-31
Braidwell LP 3,105,2092026-03-31
Frazier Life Sciences Management, L.P. 2,630,6652026-03-31
Vanguard Capital Management LLC2,470,4082026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AUTLAutolus Therapeutics plc $1.46 -13.61% -1.35 — 0.00%
CBLL $18.81 +3.07% -11.62 $713.70M 0.00%
EHABEnhabit Inc $13.80 +0.07% -153.33 $706.91M 0.00%
KIDS $22.77 -0.26% -10.79 $584.85M 0.00%
KMDA $7.06 +1.00% 20.54 $407.32M 3.18%

About EOLS

EOLS is led by CEO David Moatazedi, employs 372 people, headquartered in US, publicly traded since 2018.

EOLS stock trades at $6.03 with a market capitalization of $397.10M. The stock is valued at a price-to-earnings (P/E) ratio of -9.25, price-to-book of -14.00, price-to-sales of 1.35. Over the past 52 weeks the stock has ranged between $3.86 and $9.58, and currently trades 37.1% below its 52-week high.

On profitability, EOLS generates a return on equity (ROE) of 174.92% — well above the market average, a sign of a high-quality business, return on capital employed of -18.91%, an operating margin of -12.79%, a net profit margin of -14.39%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides